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Abstract 
Sarcoma-like cells (SCLs) were derived from endarterectomized tissue of a 
single chronic thromboembolic pulmonary hypertension (CTEPH) patient 
during incubation of those thrombi at second passage as described at our 
previous report. These cells had malignant potential, with an increased 
expression of matrix metalloproteinase-14 (MMP-14), leading to tumor 
emboli within pulmonary arteries in in vivo studies. The purpose of this 
study was to perform a more detailed evaluation of the characteristics of 
SCLs, and to elucidate the role of the increased expression of MMP-14 
expression in the growth and death of these cells. In order to elucidate the 
characteristics of SCLs and to confirm the protein expression of MMP-14, 
three-dimentional culture, invasion assays, a Western blot analysis and 
immunohistochemical studies were performed. To examine the role of 
MMP-14 in tumorigenesis, the metalloproteinase inhibitor, batimastat, was 
administered to SCID mice which were subcutaneously injected with SCLs. 
Those mice were sacrificed on day 14 and the tumor volume was evaluated. A 
Western blot analysis showed the increased expression of MMP-14 in 
comparison to the expression in lung adenocarcinoma cells (A549). 
Immunohistochemistry showed that SCLs were positive for vimentin, 
MMP-14,  MMP-2 and CD44. However, endothelial markers, such as CD31 
and von Willebrand factor (vWF), were negative. The in vivo studies 
demonstrated that batimastat could suppress the growth of the 
subcutaneous tumors formed by the SCLs. This study suggested that MMPs 
had critical roles on the pathological activities of SCLs and that batimastat 
might have anti-proliferative and anti-invasive effects on these cells.  
Introduction 
The organized thrombi of chronic thromboembolic pulmonary 
hypertension (CTEPH) are composed of several cell phenotypes. Some 
populations have high biological activities [1], and some are positive for 
α-smooth muscle actin (α-SMA), which were considered to be 
“myofibroblast-like cells” from the endarterectomized tissues of the CTEPH 
patient [1, 2, 3]. We previously showed that the myofibroblast-like cells were 
hyperproliferative, invasive and anchorage-independent [3], and these 
characteristics are considered to be cancer hallmarks [4]. We also showed 
that sarcoma-like cells (SCLs) derived from a single CTEPH patient could be 
isolated at the second passage of the myofibroblast-like cells, and these had 
an increased expression of matrix metalloproteinase-14 (MMP-14), and had 
high tumorigenic potential to form solid and undifferentiated tumors which 
grew along the intimal surface of the pulmonary arteries in 
C.B-17/lcr-scid/scidJcl mice [5]. These results suggested that the behavior of 
SCLs closely resembled that of pulmonary intimal sarcoma. Pulmonary 
intimal sarcoma is a very rare mesenchymal neoplastic tumor [6] that is 
highly resistant to treatments, including anti-cancer drugs.   
The purpose of this study was to obtain more details about the 
characteristics of SCLs in comparison to A549 epithelial cancer cells, and to 
elucidate the role of the increased expression of MMP-14 in the growth and 
death of the cells. This is the further report focusing on MMP-14 following 
our previous report [5]. The results of this study may lead to the 
development of a new therapeutic approach for this uncommon sarcoma.  
 
Materials and methods 
Ethic statement 
All procedures performed in this study were approved by the Research 
Ethics Committee of Chiba University School of Medicine and Chiba 
University Instrumental Animal and Use Committee. Written informed 
consent was given by all subjects. 
 
Clinical presentation of the patient 
SCLs were derived from a single patient. The patient was a 64 years-old man 
with a history of acute pulmonary embolism and consulted to a hospital 
because of hemoptysis, which was treated by a bronchial artery embolization 
(BAE) procedure. The results of detailed examinations diagnosed him as 
pulmonary hypertension and pulmonary arterial embolism. Therefore, he 
was referred to our hospital. Preoperative hemodynamic data was as follows, 
mean pulmonary arterial pressure (mPpa); 55mmHg, pulmonary vascular 
resistance (PVR); 982 dyne sec cm-5. By computed tomographic (CT) scan, 
lung perfusion scan, and pulmonary angiography, chronic pulmonary 
embolism was detected. He was diagnosed as CTEPH and pulmonary 
endarterectomy (PEA) was performed by Dr. Masahisa Masuda at the Chiba 
Medical Center, Japan. After the surgery, the hemodynamic improved as 
follows, mPpa ; 17 mmHg, PVR; 202 dyne sec cm-5. Resected organized 
thrombi were investigated pathologically. Pathological diagnosis was 
atherosclerosis-intima fibrosis of pulmonary arteries with partial 
recanalization, which was the typical finding of chronic pulmonary 
thrombosis, and no malignant cell was detected. Although it’s already been 
five years or more after the operation, he has no intimal sarcoma now.  
 
Cell isolation.  
One part of resected organized thrombi was investigated pathologically and 
the other part was done in this study. At the second passage of the 
myofibroblast-like cells obtained following incubation of the 
endarterectomized tissues, pleomorphic cells (called sarcoma-like cells 
(SCLs)), were isolated, probably by chance. The details of the cell isolation 
have been described previously [5].  
 
Cell lines and reagents.  
A549 cells (a human lung carcinoma cell line) were purchased from Takara 
Biomedical (Ohtsu, Shiga, Japan). SCLs were incubated using endothelial 
cell growth medium supplemented with 5% fetal bovine serum (FBS) and 
growth factors (EGM-2) (Lonza Inc, Allendale, NJ, USA) at 37℃ in 5% CO2 
in air in a humidified incubator. A549 cells were cultured using RPMI 1640 
media (Life Technologies, Carlsbad, CA, USA) with 5% FBS. In order to 
exclude the effects of several growth factors present in the EGM, endothelial 
cell basal medium-2 (EBM-2) (Lonza Inc, Allendale, NJ, USA), with only 5% 
FBS, was used in some experiments. Batimastat, a synthetic matrix 
metalloproteinase inhibitor, was purchased from Merck Millipore 
(Darmstadt, Germany). Batimastat was diluted in dimethyl sulfoxide, stored 
at -20℃ and was prepared just before use in experiments. The antibodies 
used for the immunohistochemical studies were: mouse anti-vimentin (1:200, 
Dako, Carpinteria, CA, USA), mouse anti-human, rabbit anti-von 
Willebrand factor (factor VIII) (1:1,000, Dako), rabbit anti-CD31 (1:200, 
Abcam, Cambridge, UK), anti-MMP-14 (1:200), rabbit anti-MMP-2 (1:200, 
Abcam), mouse anti-CD44 (1:100, Abcam), an anti-mouse IgG conjugated 
with Alexa-488 fluorescent dye (1:200, Molecular Probes, Tokyo, Japan), an 
anti-rabbit IgG conjugated with Alexa-488 fluorescent dye (1:200, Molecular 
Probes), rabbit anti-MMP-14 (1:200, Abcam), MMP-2 (1:100, Abcam) and 
polyclonal biotinylated goat anti-rabbit immunoglobulins (1:500, Dako). The 
antibodies used in the Western blot analysis were: MMP-14 antibodies (1:500, 
Abcam), MMP-2 antibodies (1:500, Abcam), β-actin antibodies (1:1000, Cell 
Signaling Technology, Boston, MA, USA) and stabilized goat anti-rabbit IgG 
(H+L), which was peroxidase conjugated (ThermoScientific, Massachusetts, 
MA, USA). 
 
PCR array.  
In order to confirm the different RNA expression levels between SCLs as 
mesenchymal malignant tumor cells and A549 as epithelial cancer cells, a 
PCR array analysis focusing on the adhesion molecules was performed. Our 
previous study had demonstrated that there was increased mRNA 
expression of MMPs in SCLs in comparison to A549 cells [5]. Therefore, a 
PCR array was used to confirm the precise expression levels of various 
MMPs. The RT2 Profiler PCR Array (SABiosciences, Frederick, USA) was 
used for this purpose. The details of this protocol have been described 
previously [5]. 
 
Invasion and migration assay.  
The BD BioCoat FluoroBlok Invasion System (24-multiwell) was used to 
assess the invasion and migration of SCLs with or without batimastat 
treatment. In order to exclude the effects of additives, including growth 
factors, SCLs were incubated with the EBM-2 for three days. Then, 2.5×10５ 
pretreated SCLs were seeded to each upper well of the kit with serum free 
medium. The medium added to each lower well was as follows: EBM-2 
containing 5% FBS and dimethyl sulfoxide (the same quantity as the solvent 
used for dissolving 10 μM batimastat) (control group), 5% FBS and 1 μM 
batimastat (1 μM batimastat group) or 5% FBS and 10 μM batimastat (10μM 
batimastat group). The kits were incubated at 37℃ in 5% CO2, in a 
humidity-controlled incubator for 16 hours. The fixation, staining and 
quantification of the invaded cells were described previously [5]. 
 
Three-dimensional cultures.  
BD Matrigel™ Basement Membrane Matrix Growth Factor Reduced (BD 
Falcon, USA) was used for three-dimensional cultures. This experiment was 
conducted in accordance with the recommended "thin-gel method". Matrigel 
was gently thawed in a 4℃ refrigerator. A 50 μl aliquot of Matrigel was 
added thinly to each wells of a 24-well plate. The plates were incubated in a 
37℃ incubator for 15 minutes. After that, 20 μl of Matrigel and 5×104 cells 
suspended in 1000 μl medium were mixed and seeded into each well. The 
findings in SCLs and A549 were investigated. In order to study the effects of 
batimastat, 1 μM or 10 μM of batimastat were added to the EBM-2 media. 
Finally, the plates were incubated at 37° in a 5% CO2 in air in a humidified 
incubator for different periods of time. 
 
Western blot analysis.  
The cultured cells on the dishes were washed, homogenized in lysis buffer 
(20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM NaN3, 1 mM DTT, 150 mM 
NaCl, 0.5% Triton-X, phosphatase inhibitor cocktail (SIGMA P5726)), and 
centrifuged at 10,000 x g for 5 min. The protein concentrations of these 
supernatants were measured by the Bradford method (Bio-Rad protein 
assay; Nippon Bio-Rad Laboratories, Tokyo, Japan). Protein samples (2 μg) 
were separated on 10% Tris-glycine gels (Invitrogen Japan, Tokyo, Japan) 
and transferred to nitrocellulose membranes (Invitrogen Japan, Tokyo, 
Japan). Membranes were blocked with 5% non-fat dried milk in PBS 
containing 0.5% Tween20 for 1 hour at 4℃, and were then incubated with 
primary antibodies. The membranes were incubated with 
peroxidase-conjugated secondary antibodies for 1 hour at room temperature. 
Chemiluminescence was detected by a LAS-1000 instrument (Fuji Film, 
Tokyo, Japan). Signals were quantified using the Fuji Image Gauge software 
program (ver. 3.0, Fuji Film, Tokyo, Japan). 
 
Cell culture with a matrix metalloproteinase inhibitor.  
SCLs were incubated with growth factor-free medium for three days. They 
were then washed and trypsinized. A total of 1×105 cells were added to 
fibronectin-coated dishes. They were incubated with the EBM-2 containing 
DMSO (control group), 1 μM batimastat (1 μM batimastat group) or 10 μM 
batimastat (10 μM batimastat group) at 37° in a 5% CO2 in air in a 
humidified incubator for 24 hours, 48 hours or 72 hours. At the appropriate 
times, the cell numbers were counted. 
 
Intravascular and subcutaneous tumor formation.  
Icr/scid mice were purchased from Nihon Clea. SCLs incubated in EGM 
media were trypsinized, and 2×106 cells were injected intravenously into the 
mice. Twenty-eight days after injection, the mice were sacrificed, and various 
organs, including the lungs, were resected. These tissues were pathologically 
investigated. A total of 1×106 cells were injected subcutaneously into the 
Icr/scid mice. Then 40 mg/kg batimastat was injected intraperitoneally once 
a day from day 3 to day 13. On day 14, they were sacrificed, and the 
subcutaneous tumors were resected. Tumors were weighed and 
pathologically examined. 
 
Immunohistochemistry.  
Samples were fixed in 10% buffered formalin, paraffinized and sliced at 1.5 
μm thick. Antigen retrieval was performed using pH 6.0 citrate buffer 
(Abcam # 64214) for the deparaffinized slices. Sections were blocked with 2% 
normal goat serum, PBS(-) and 0.1% Tween20 for 30 min at room 
temperature. They were then incubated with the primary antibodies for 1 
hour at 4℃ and with secondary antibodies for 30 minutes at room 
temperature. The avidin-biotin-peroxidase complex method with peroxidase 
streptavidin (Nichirei #426062, Tokyo, Japan) and the DAB substrate kit 
(Abcam ab64238) was performed. 
 
Statistical analysis.  
The PCR array data were analyzed by a web-based software program, the 
RT2 Profiler PCR Array Data Analysis, version 3.5 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). The other 
data were analyzed using the useful and reliable statistical software, EZR on 
R commander [7] (ver.1.03, provided on the site of Division of Hematology, 
Saitama Medical Center, Jichi Medical University 
(http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html)). At 
least three samples were used for the statistical analyses. We considered 
that the differences were significant for values of p < 0.05. 
 
Results 
MMPs expression.  
The PCR array analysis showed that there was increased mRNA expression 
for MMP-2, MMP-14 and MMP-16 in the SCLs in comparison to the A549 
cells (Table 1, Figure 1). In addition, decreased expression of MMP-7 mRNA 
was confirmed in SCLs in comparison to the A549 cells (Table 1, Figure 1). A 
Western blot analysis revealed that the MMP-14 protein expression in SCLs 
was higher than that in A549 (Figure 2A). There was no obvious difference in 
the protein expression of MMP-2 and MMP-14 in the SCLs incubated in the 
media with (EGM) or without (EBM) growth factors (Figure 2A).  
 Immunohistochemistry.  
Immunohistochemical staining showed that SCLs were positive for vimentin 
(Figure 3A), MMP-14 (Figure 3F), MMP-2 (Figure 3G) and CD44 (Figure 3H) 
which is a cell-surface glycoprotein involved in cell adhesion and migration. 
However, endothelial cell markers, including Factor VIII (Figure 3B) and 
CD31 (Figure 3C), a smooth muscle cell marker, α-SMA (Figure 3D) and 
desmin (Figure 3E) were negative. C.B-17/lcr-scid/scidJcl mice which were 
intravenously injected with SCLs developed tumors which grew along the 
intimal surface of the pulmonary arteries (Figures 4A, 4B). The peripheral 
lesions of tumors seemed to be a cell-rich layer, while the center of the 
tumors was a necrotic zone (Figure 4B). The cells in the tumor were positive 
for MMP-14 and MMP-2 (Figures 4C, 4D). 
 
Three-dimensional culture.  
The three-dimensional culture system was employed to confirm the SCL 
proliferation under in vivo conditions, which could make the cells grow in an 
environment that more closely resembled their normal condition. SCLs, as 
mesenchymal neoplastic cells, formed aligned structures as tube-like 
networks during the 12-hour incubation period (Figure 5A). In contrast, the 
A549 adenocarcinoma cells did not organize themselves into aligned 
structures (Figure 5B). 
 
Effects of a synthetic matrix metalloproteinase inhibitor, batimastat.  
In order to confirm the role of MMPs in the growth and death of SCLs, the 
cells were incubated in the EBM-2 media with batimastat. Although 
batimastat did not suppress the protein expression of MMP-14 or MMP-2 
(Figures 2B-2D), this reagent did suppress the number of proliferating SCLs 
(Figure 6A). Moreover, the invasion assay demonstrated that batimastat 
decreased the invasion of SCLs (Figure 6B), and the three-dimensional 
culture showed that it prevented these cells from organizing themselves into 
aligned tube-like structures (Figures 5C, 5D). 
To investigate the effects of batimastat on the tumorigenesis of SCLs in 
Icr/scid mice, 1×106 cells were injected subcutaneously, and were then 
treated intraperitoneally with 40 mg/kg batimastat once a day from day 3 to 
day 13. On day 14, the resected subcutaneous tumors were weighed, and 
there was a significant difference between the control (n=6) (Figure 7A) and 
batimastat (n=4) (Figure 7B) groups (control group 267.5±113.8 mg vs 
batimastat group 112.9± 56.4 mg, p<0.05) (Figure 7C). There were no 
significant differences in the body weight between the groups on the day of 
SCLs injection (day 0: control group 20.6±1.0g vs batimastat group 21.7±0.8 
g, p>0.05) or on the first day of batimastat injection (day 3: control group 
21.7±0.9 g vs batimastat group 22.3±0.8 g, p>0.05). On day 14, there was a 
significant difference in the body weight between the groups (control group 
20.7±0.8 g vs batimastat group 22.2±0.7 g, p<0.05). 
  Discussion 
The present study demonstrated that there was an increased expression of 
MMP-14 in SCLs (Figures 1-4) and that the blockade of the MMPs cascades 
by batimastat suppressed the pathobiological activities of SCLs in in vivo 
and in vitro experiments (Figures 5-7). MMPs are a group of endopeptidases 
biochemically characterized by their dependence on zinc at the active site [8, 
9]. MMPs degrade most components of the extracellular matrix (ECM) and 
are considered to have an important role in various biological processes in 
cells, such as proliferation, apoptosis, invasion, differentiation and 
angiogenesis [8, 9]. Generally, MMPs are divided into two groups; 
secretion-type and membrane-type (MT). Because of its cell surface 
expression, MMP-14 is called MT1-MMP [10, 11, 12]. MMP-14 has many 
functions, including ECM degradation, the activation of MMP-2 and 
MMP-13 [11, 13] and the cleavage of cell surface receptors, such as CD44 [10, 
11, 13]. Therefore, because MMP-14 is a modulator of the pericellular 
microenvironment [10], it is thought to have critical roles in controlling the 
invasive and metastatic capabilities of malignant cells [10, 11].  
Batimastat is a synthetic MMP inhibitor, and the depressant action of this 
agent is biochemically explained by the binding of a hydroxamate to the zinc 
ion in the active center of MMPs [14]. In this study, batimastat inhibited the 
proliferation of SCLs (Figure 6A). Some studies, however, reported that 
batimastat did not suppress the proliferation of malignant cells [15, 16]. 
Zervos et al. showed that anti-proliferative effect of this drug on human 
pancreatic adenocarcinoma cells was apparent in a high dose of this drug 
[17], indicating that anti-proliferative effect of this drug might be in a 
dose-dependent manner. This supports our results on Figure 6. Moreover, 
batimastat suppressed invasive activity of SCLs in the present study. Ueda 
et al. also reported that the invasive fibrosarcoma cells were suppressed by 
10μM batimastat [18]. In truth, MMP-14 is supposed to play a critical role on 
cell invasion activity through effect as the degeneration of extracellular 
matrix [12, 19]. 
Kadono et al. reported that batimastat inhibited the formation of 
three-dimensional structures by fibrosarcoma cells [20], as well as their 
migration and adhesion [21]. In this study, SCLs formed tube-like or 
network-like structures in the three-dimensional culture, and batimastat 
prevented the formation of these structures by the SCLs (Figure 5). This 
result supported the findings in the previous report. However, A549 cells 
could not form the tube-like or network-like structures in the 
three-dimensional culture (Figure 5B), and these differences are likely 
attributable to the fact that the SCLs were mesenchymal cells which had 
originated from the pulmonary vasculature, while A549 cells are cancer cells 
of epithelial origin. Moreover, the mRNA and protein expression levels of 
MMP14 in SCLs were higher than those in A549 cells (Figures 1 and 2A), 
leading to a higher potential for the degradation of the extracellular matrix 
by the SCLs, which might explain the results of the three-dimensional 
culture experiments. In fact, there was a previous report that described that 
the MMP-14 expression level was strongly related to the formation of 
three-dimensional structures by malignant cells [22].  
The Western blot analysis demonstrated that the protein expression levels 
of MMP-2 and MMP-14 did not decrease, but were actually slightly increased 
after the batimastat treatments (Figure 2), indicating that, as expected 
based on its putative mechanism of action, batimastat could suppress only 
the activities of MMPs, rather than affecting their protein expression levels. 
In addition, the positive feedback induced by the blockade of the activity of 
MMPs might have led to the increased expression of MMP-2 and MMP-14 in 
these cultures.  
In the present study, batimastat could suppress the development of 
subcutaneous tumors in Icr/scid mice (Figure 7), supporting the previous 
reports showing the effectiveness of this reagent for controlling the growth of 
other tumors, such as ovarian carcinoma [23], breast cancer [24], pancreatic 
cancer [17], a human colon cancer model [25] and a metastatic human colon 
carcinoma model [15]. However, the details of the fundamental mechanisms 
by which batimastat prevents tumor growth remain to be elucidated. In this 
study, batimastat could suppress the enlargement of SCL tumors and 
maintain the weight of mice. It is known that maintenance of the body 
weight by patients with malignant tumors contributes to a better quality of 
life [26]. Therefore, it was supposed that both the tumor growth suppression 
and the effect on the mouse body weight were important for the anti-cancer 
effects of batimastat. 
The findings from this study and the previous study [5] suggest that the 
behavior and the characteristic of SCLs resemble those of pulmonary intimal 
sarcoma cells. Clinically, intimal sarcoma is an extremely rare disease, and 
to the best of our knowledge, there have been no cell lines isolated from 
intimal sarcoma tissues. Pulmonary intimal sarcoma is believed to originate 
from the mesenchymal cells present within the intimal layer of pulmonary 
arteries [27]. Vasuli et al. previously described the immunohistochemical 
characteristics of pulmonary intimal sarcoma tissues, indicating that the 
cells of intimal sarcoma were positive for the mesenchymal cell marker, 
vimentin, negative for the endothelial cell markers von-Willebrand factor 
(VWF) and CD31, and for the smooth muscle cell marker, α-smooth muscle 
actin [28]. In addition, this study also described that the undifferentiated 
intimal sarcoma cells were positive for mesenchymal stem cell markers, such 
as RUNX-1 or CD44 [28]. As described above, the SCLs in the present study 
were positive for vimentin and CD44 and negative for CD31 and VWF, 
α-smooth muscle actin and desmin (Figure 3). SCLs had some characteristics 
which resemble those of pulmonary intimal sarcoma. However, SCLs were 
derived from only one patient with CTEPH and the isolation of SCLs was not 
reproducible. CTEPH and pulmonary initimal sarcoma are completely 
different diseases and it remains unknown how and why this only one cell 
line represents characteristics of initimal sarcomas.   
In conclusion, this study suggested that MMPs had critical roles on the 
pathological activities of SCLs and that batimastat might have 
anti-proliferative and anti-invasive effect on these cells.  
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Figure legends 
Figure 1: The results of the PCR array analysis focused on the matrix 
metalloproteinases (MMPs) of SCLs.  
The expression levels of MMP-14 and MMP-2 of SCLs were higher than 
those of A549 cells, while the level of MMP-7 was lower. These data were 
analyzed by a web-based software program (the RT2 Profiler PCR Array Data 
Analysis, version 3.5). Error bars showed 95% Confidencial intervals. (* 
p-value <0.05 versus A549, n=5) 
 
Figure 2: The results of the Western blot analysis.  
(A) The Western blot analysis revealed that the MMP-14 protein expression 
in SCLs was higher than that in A549 cells. There was no significant 
difference in the protein expression of MMP-14 in SCLs incubated in the 
media with or without growth factors. (B) Batimastat did not suppress the 
SCLs’ expression of the MMP-14 and MMP-2 proteins.  
(C)(D) The band signal strength of MMP-14 (c) and MMP-2 (d) expressed as a 
ratio to beta-actin. No significant differences in the signal strength were 
recognized 24 hours and 48 hours after batimastat exposure between the 
batimastat and control groups. 
(“N.S.” showed no significant difference between two groups analyzed by 
Student’s t-test.) 
 
Figure 3: The results of the immunohistochemical analysis of the SCLs.  
The SCLs were positive for vimentin (A), MMP-14 (F), MMP-2 (G) and CD44 
(H). In contrast, the staining for α-SMA (B), VWF (C), CD31 (D) and desmin 
(E) was negative. (Scale bars show 50μm.) 
 
Figure 4: Tumors which grew along the intimal surface of the pulmonary 
arteries.  
(A) A resected lung from a mouse. SCID mice were sacrificed 28 days after 
the injection of SCLs. Many nodules were located on the surface of the 
lungs. Arrow heads showed some of these nodules. 
(B) HE staining showed that the tumors were composed of a central area 
with necrosis and a peripheral zone filled with SCLs.  
(C) Immunohistochemical staining for MMP-14 revealed that the peripheral 
area of tumors was positive for MMP-14, and the central necrotic area 
was negative for MMP-14.  
(D) Immunohistochemical staining for MMP-2 showed that MMP-2 was 
weakly positive in the peripheral zone. (Scale bars show 100μm.) 
 
Figure 5: The findings of the three-dimensional culture of SCLs.  
Cells were incubated for 12 hours (A and B) or 24 hours (C and D). SCLs 
proliferated linearly and formed tube-like structures and network-like 
structures within Matrigel (A), but the A549 (lung adenocarcinoma) cells 
formed no network structures (B). SCLs incubated with EBM-2 also formed 
the tube-like structures in the Matrigel (C). Exposure to 10 μM batimastat 
inhibited the formation of the three-dimensional structures (D). (Scale bars 
show 300μm.) 
 
Figure 6: Batimastat suppressed the biological activities of SCLs in in vivo 
studies. 
(A) Batimastat, a synthetic matrix metalloproteinase inhibitor, suppressed 
the proliferation of SCLs 72 hours after incubation with batimastat. The 
number of SCLs that survived following the culture with batimastat was 
lower than that in the control group. (* p-value <0.05, **p-value<0.01 versus 
control group, by Student’s t-test, n=6) 
(B) The invasion assays revealed that the SCLs incubated with batimastat 
were less invasive than those in the control group. (* p-value <0.05 versus 
control group, **p-value<0.01 versus control group, by Student’s t-test, n=8) 
 
Figure 7: Batimastat suppressed the growth of SCLs in xenograft models.  
Subcutaneous tumors were formed on the backs of the mice in the control 
group (A) and batimastat group (B). It was revealed that there were 
significant differences in the tumor weights between the control group (n=6) 
and batimastat group (n=4) (C). (* p-value <0.05, versus control group, by 
Student’s t-test) 
 
  
Table 1 
Expressions of matrixmetalloproteinase of SCLs on PCR array. 
Description Gene symbol Public ID Fold Change (95%CI) p-value 
Matrix metallopeptidase 1 (interstitial collagenase) MMP1 NM_002421 1.2872 ( 0.00001-2.77 ) N.S. 
Matrix metallopeptidase 2 (gelatinase A, 72kDa 
gelatinase, 72kDa type IV collagenase) 
MMP2 NM_004530 25.9049 ( 0.00001-60.45 ) <0.05 
Matrix metallopeptidase 3 (stromelysin 1, 
progelatinase) 
MMP3 NM_002422 -0.4998 (-1.10- -0.00001) N.S. 
Matrix metallopeptidase 7 (matrilysin, uterine) MMP7 NM_002423 -0.037 (-0.06- -0.01) <0.00005 
Matrix metallopeptidase 8 (neutrophil collagenase) MMP8 NM_002424 -0.4566 (-1.11- -0.00001) N.S. 
Matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 
MMP9 NM_004994 0.9158 ( 0.00001-2.04 ) N.S. 
Matrix metallopeptidase 10 (stromelysin 2) MMP10 NM_002425 1.1935 ( 0.00001-3.16 ) N.S. 
Matrix metallopeptidase 11 (stromelysin 3) MMP11 NM_005940 0.8688 ( 0.00001-2.01 ) N.S. 
Matrix metallopeptidase 12 (macrophage elastase) MMP12 NM_002426 1.3401 ( 0.24-2.44 ) N.S. 
Matrix metallopeptidase 13 (collagenase 3) MMP13 NM_002427 1.5681 ( 0.05-3.09 ) N.S. 
Matrix metallopeptidase 14 (membrane-inserted) MMP14 NM_004995 90.8284 ( 27.28-154.38 ) <0.01 
Matrix metallopeptidase 15 (membrane-inserted) MMP15 NM_002428 2.573 ( 0.93-4.22 ) N.S. 
Matrix metallopeptidase 16 (membrane-inserted) MMP16 NM_005941 7.9291 ( 2.24-13.62 ) <0.05 
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